[Perspectives in cardiology: evidence of efficacy in atrial fibrillation and hopes in acute coronary syndrome].
New antithrombotic drugs, antithrombin or anti Xa, will probably be very useful in cardiology. Two directions are interesting: in one hand atrial fibrillation, in which the unmet need concern drugs as effective as vitamine K antagonists but easier to use. On the other hand, in acute coronary syndrome the situation is different, there are many antithrombotic drugs available but there is still a place for innovative drugs which could provide a gain in terms of efficacy, but the hemorrhagic risk must remain acceptable. In atrial fibrillation, the RELY trial, performed in 18,113 patients has demonstrated, as compared to warfarin, a non inferiority of dabigatran at the dose of 110 mg BID and a superiority of dabigatran at 150 mg BID with a reduction of 34% of the primary endpoint, i.e.stroke and systemic embolism.
Le Heuzey
J-Y
JY
Service de Cardiologie A et Rythmologie, Hôpital Européen Georges Pompidou, 20, rue Leblanc, 75015 Paris, France. jean-yves.le-heuzey@egp.aphp.fr
Marijon
E
E
Otmani
A
A
Lepillier
A
A
Waintraub
X
X
Lavergne
T
T
Pornin
M
M
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans
D005343:Fibrinolytic Agents